Solventum (NYSE:SOLV) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker6Good afternoon. My name is Audra, and I will be your conference call operator today. I would like to welcome everyone to Solventum's fourth quarter 2025 earnings call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise. I would now like to turn the program over to your host for today's conference, Amy Wakeham, Senior Vice President of Investor Relations and Fina ...

Summary of Baxter International 2026 Conference Call Company Overview - **Company**: Baxter International (NYSE: BAX) - **Date of Conference**: February 26, 2026 Key Industry Insights - **Medtech Fundamentals**: The underlying fundamentals of the medtech industry are described as solid and stable, despite stock performance concerns. Patient volumes and procedure volumes are in a decent place, with no significant hyperinflationary pressures noted [12][13]. - **IV Solutions Market**: Demand for IV solutions has decreased by approximately 10-15% from pre-hurricane levels, establishing a new baseline for the market. This decline is attributed to changes in clinical practices following a hurricane [13][14][41]. Company-Specific Developments - **Leadership Changes**: The arrival of a new CEO, Andrew, is seen as timely for Baxter, allowing the company to build on a clearer operational foundation after recent distractions from divestitures [20][21]. - **Operational Model**: The introduction of a new operating model (GPS) aims to enhance consistency in operations and performance tracking. This model is expected to lead to improved operational predictability [22]. - **Verticalization Strategy**: Baxter is evolving its business structure to allow for end-to-end ownership of profit and loss (P&L), moving away from a country-led structure. This change is intended to streamline decision-making and improve accountability [29][30][37]. Financial Performance and Guidance - **2026 Guidance**: The guidance for 2026 is described as prudent, factoring in challenges and opportunities. It does not include any sales from the Novum product, which is under a voluntary shipping hold [101][103]. - **Margin Expectations**: The company anticipates sequential improvement in gross and operating margins throughout 2026, particularly in the second half of the year, as operational issues are resolved [116][118]. - **Capital Allocation**: Baxter is focused on deleveraging its balance sheet, targeting a debt-to-EBITDA ratio of three times by the end of the year. Internal investments in R&D and capital spending remain a priority [131][134]. Product Innovations - **New Products**: The Connex 360, a next-generation monitoring device, and the Dynamo, a connected stretcher, are highlighted as key innovations expected to drive growth in 2026. Customer feedback has been positive for these products [76][78]. Challenges and Risks - **Supply Chain Issues**: The company has faced supply challenges in its pharmaceutical business, which have impacted production and market performance. These issues are expected to improve in the second half of 2026 [47][110]. - **Tariff Changes**: Uncertainty surrounding tariff changes is acknowledged, with ongoing efforts to assess their impact on the business [99][100]. Conclusion - Baxter International is positioned at a pivotal point, focusing on stabilizing operations, improving financial performance, and driving innovation. The company aims to build credibility with stakeholders through consistent execution and strategic growth initiatives as it moves into 2026 [145][151].

Financial Data and Key Metrics Changes - For the full year 2025, the company reported net sales of $701 million, exceeding the revised guidance range, and generated adjusted diluted earnings per share of $0.94 [4][11] - The adjusted EBITDA for the year was $87 million, with an adjusted gross margin of 54.6% and adjusted SG&A as a percentage of revenue of 42% [12][19] - For Q4 2025, net sales were approximately $181 million, with adjusted diluted earnings per share of $0.29 and adjusted EBITDA of $28 million [11][19] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems portfolio grew over 8% organically compared to the prior year, driven by strong demand in long-term and short-term enteral feeding products [6][15] - The Pain Management & Recovery portfolio saw normalized organic sales increase by 2.3%, with the radiofrequency ablation business posting double-digit organic growth [7][18] - The Game Ready portfolio experienced a slight decline year-over-year but maintained similar revenue levels throughout 2025 [9][18] Market Data and Key Metrics Changes - The Specialty Nutrition Systems segment's operating profit was 19%, down 100 basis points from the previous year due to unfavorable tariff impacts [17] - The Pain Management & Recovery segment's operating profit improved by 270 basis points to 4%, reflecting effective cost management despite tariff costs [18] - The hyaluronic acid injections and IV therapy product lines reported a decline of over 35% compared to the prior year due to the divestiture of the HA business [19] Company Strategy and Development Direction - The company is focused on five strategic imperatives: accelerating organic growth, managing tariff impacts, realizing operating efficiencies, improving or divesting underperforming assets, and acquiring synergistic businesses [10][23] - The company is executing a China exit strategy, aiming to have all syringe manufacturing operations out of China by June 2026 [12][21] - The integration of Nexus Medical into the neonatal portfolio is progressing well, with expectations for double-digit growth in 2026 [13][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for continued growth in 2026, despite anticipated tariff impacts [20][23] - The company expects net sales in the range of $700 million to $720 million for 2026, with mid to high single-digit growth in the Specialty Nutrition Systems segment [21] - Management highlighted the importance of ongoing tariff mitigation strategies and the expected improvement in gross margins in the second half of 2026 [20][34] Other Important Information - The company generated $43 million of free cash flow for the full year, higher than anticipated due to timing of one-time cash charges [19][20] - Capital expenditures for 2026 are expected to be around $25 million, slightly lower than 2025, to support the accelerated China exit plan [22] Q&A Session Summary Question: Insights on tariffs and 2026 outlook - Management estimated a $30 million impact from tariffs in 2026, with a significant portion related to China [27][29] - The company is confident in exiting China by June and delivering products from Mexico and Cambodia [28][30] Question: Revenue guidance and organic growth rates - The consolidated organic growth rate is expected to be around 5%, with mid to high single digits for Specialty Nutrition Systems and low to mid single digits for Pain Management & Recovery [36][37] Question: Operating leverage and cost-saving initiatives - Management expressed high confidence in continuing to drive efficiency in 2026, with a focus on both R&D and SG&A [38][39] - Cost containment measures are expected to offset additional tariff expenses and support earnings expansion [41] Question: Specialty Nutrition performance and Nexus acquisition - Demand for the Specialty Nutrition Systems portfolio remains high, with Nexus performing better than expected and contributing to growth [42][44]

AI医疗技术公司Tempus AI宣布，推出其新型HRD-RNA癌症 检测 算法。与传统DNA检测不同，Tempus 基于RNA的方法通过分析基因表达而非结构性DNA损伤，提供对肿瘤功能状态的实时评估。这种方法 使该模型能够在基因组瘢痕难以识别的患者和癌症类型中检测出HRD。据该公司称，一项真实世界验 证研究显示，接受一线铂类治疗方案的HRD-RNA阳性转移性胰腺癌患者，与接受非铂类一线治疗的患 者相比，死亡风险显著降低。完整的支持数据将于今年晚些时候发表。（格隆汇） ...

Core Viewpoint - Tempus AI has launched a new HRD-RNA cancer detection algorithm, which offers real-time assessment of tumor functional status by analyzing gene expression rather than structural DNA damage, marking a significant advancement over traditional DNA testing methods [1] Company Summary - Tempus AI's stock rose over 7%, reaching $56.31 following the announcement of the new HRD-RNA cancer detection algorithm [1] - The new RNA-based approach allows for the detection of HRD in patients and cancer types where genomic scars are difficult to identify [1]

Group 1 - Major stock indices are experiencing declines, with Dow futures down 0.10%, S&P 500 futures down 0.27%, and Nasdaq futures down 0.59% [1] - Gold mining stocks are trading lower ahead of the market opening, with Harmony Gold down 4.2%, Newmont down 3%, Sibanye Stillwater down 5.8%, and Barrick Gold down 2.4% [1] - AI application stocks are also down, with SAP SE falling nearly 3%, AppLovin down over 2%, and Palantir and Snowflake both down over 1% [1] - Chinese concept stocks are seeing gains before the market opens, with Alibaba up 0.80%, Pinduoduo up 0.53%, NetEase up 0.19%, Baidu up 1.45%, and JD.com up 0.29% [1] - Spot gold briefly fell below $4900, trading down 1.40% at $4922.2 per ounce, while spot silver dropped over 4%, down 2.32% at $74.6 per ounce [1] Group 2 - SpaceX and its subsidiary xAI are reportedly participating in a highly classified Pentagon bidding process aimed at developing voice-controlled autonomous drone swarm technology [2] - Elon Musk announced that the Cybercab, which will not have pedals or a steering wheel, is set to begin production in April [2] - Apple has announced a significant upgrade for Apple Podcasts, introducing video podcast functionality this spring to enhance its presence in the video podcasting space [2] - Danaher is nearing a deal to acquire medical technology company Masimo for approximately $10 billion [2]

百特国际公司(Baxter International Inc.)(NYSE:BAX) 股价暴跌14%，此前这家全球医疗技术领导者公布的第四季度业绩未达分析师预期，并发布了 令人失望的全年盈利指引。 按业务部门划分，医疗产品与疗法销售额增长6%至13.9亿美元，医疗系统与技术增长5%至8.27亿美元，制药业务增长4%至6.68亿美元。 百特最近推出了一种新的运营模式，旨在简化组织结构并提升业绩。Hider补充道："虽然前方的工作需要时间，但我对员工的奉献精神感到鼓 舞，并对百特的长期发展轨迹保持信心。" 公司还宣布了董事会变动，任命Michael R. McDonnell为新董事，而Cathy R. Smith和Stephen H. Rusckowski将于2026年2月13日辞职。 百特股价在财报发布后暴跌，因为投资者对公司业绩不及预期和2026财年疲软的展望做出反应。公司预计2026财年调整后每股收益为1.85至 2.05美元，显著低于分析师共识的2.25美元。 "虽然我们在所有业务部门都实现了销售增长，但我们第四季度的业绩未能达到我们的预期，这凸显了我们专注于推动整个企业持续改进的重要 性，"百特总裁兼 ...

Core Insights - The introduction of AI-assisted screening in breast cancer detection significantly improves screening efficacy and reduces the incidence of interval cancers, which are diagnosed between scheduled screenings [1][2] Group 1: Research Findings - The study involved approximately 106,000 Swedish women aged 40 to 74, with a follow-up period of over two years [1] - AI-assisted screening reduced the workload for radiologists by 44% and increased breast cancer detection rates by 29% compared to traditional methods [1] - The incidence of interval cancers in the AI-assisted group decreased by 12% compared to the control group, with a lower proportion of more severe cases among the remaining interval cancers [1] Group 2: Clinical Implications - AI assistance not only enhances the sensitivity of screenings, making it less likely to miss cancers, but it also does not increase the rate of false positives, which can lead to unnecessary anxiety and medical costs [2] - The results support the safety, accuracy, and efficiency of AI-assisted breast screening in clinical applications, with the technology already being implemented in some regions of Sweden and other parts of Europe [2]

Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [6] - For the full year, sales reached $1.375 billion, representing a year-over-year growth of 5.2% as reported and 5.1% in constant currency [6] - Adjusted earnings per share (EPS) for Q4 were $1.43, growing 6.7%, while full-year adjusted EPS was $4.59, an increase of 10.1% [6][23] Business Line Data and Key Metrics Changes - Orthopedic sales increased by 12.1% in Q4 and 5.5% for the full year on a constant currency basis [6] - General surgery sales grew by 3.8% in Q4 and 4.7% for the full year in constant currency [6] - U.S. orthopedic sales grew 6.6%, while international orthopedic sales increased 15.7% in Q4 [17] - U.S. general surgery sales declined by 0.4%, while international sales increased by 14.8% in Q4 [18] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased by 1.4% [17] - The decline in U.S. general surgery was attributed to a focus on exiting non-core product lines [18] Company Strategy and Development Direction - The company plans to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair [7] - A strategic decision was made to exit the gastroenterology product lines to concentrate resources on stronger growth drivers, expected to improve long-term growth margins by approximately 80 basis points [7][8] - The company aims to stabilize and scale its supply chain while building a high-performance, agile supply chain to support sustained innovation [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving above-market growth by focusing on core strengths and normalizing supply in sports medicine [15] - The company anticipates continued growth in its AirSeal and BioBrace platforms, with AirSeal expected to deliver high single-digit to low double-digit growth rates [10][13] - The CFO transition is underway, with a focus on maintaining continuity and shareholder value [16] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization, equating to approximately $0.07 EPS in 2026 [15] - Adjusted gross margin for Q4 was 56.6%, down 100 basis points from the prior year, while full-year adjusted gross margin was 56.4%, an increase of 10 basis points [21] Q&A Session Summary Question: Can you discuss the cadence for the rest of the year and any selling day differences? - Management confirmed no selling day differences and indicated that the rest of the year should follow the typical med tech calendar [32] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong team player [34] Question: Can you clarify the organic revenue numbers presented at the healthcare conference versus today? - The difference is due to final numbers rolling out, with the current guidance being more precise [37] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales beat was attributed to committed sales professionals, improving supply chain, and new product approvals, while general surgery faced challenges due to portfolio management [40][42] Question: How will the GI business be reported going forward? - The GI business will be reported separately, reflecting its exit from the main revenue figures [54] Question: What are the growth trends for AirSeal internationally? - AirSeal continues to perform within the expected growth range, with opportunities in both robotic and laparoscopic procedures [68]

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its fourth-quarter 2025 results on February 2, before the market opens [1] - The company reported adjusted earnings per share (EPS) of $3.40 in the last quarter, exceeding the Zacks Consensus Estimate by 8.28%, and has consistently beaten estimates over the past four quarters with an average surprise of 7.12% [1] Q4 Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $1.07 billion, reflecting a 12.2% increase from the previous year [2] - The EPS estimate stands at $2.93, indicating an 11.8% rise year-over-year [2] - Earnings estimates have remained stable at $2.93 over the past 60 days [3] Key Drivers of Performance - The Companion Animal Group (CAG) is expected to maintain its momentum, driven by strong commercial execution and recurring revenues from diagnostics, particularly in the U.S. and international markets [4] - IDEXX VetLab consumables are anticipated to benefit from increased test volumes and higher realized prices [4] - Key innovations such as the IDEXX inVue Dx Analyzer and IDEXX Cancer Dx panel are likely to have seen strong adoption, contributing to increased recurring revenues in Veterinary Software and Services [5] Segment Performance - CAG revenues are projected to grow by 12.7% year-over-year in Q4 2025 [7] - The Water segment is expected to see revenues increase by 7.8% year-over-year, supported by higher prices and volumes [10] - The Livestock, Poultry and Dairy (LPD) division is also anticipated to experience a 7.8% year-over-year revenue increase, driven by higher test volumes and prices across various regions [11] Earnings Model Insights - IDEXX Laboratories has an Earnings ESP of 0.00%, indicating no expected surprise in earnings [12] - The company currently holds a Zacks Rank of 2 (Buy) [13]